Walleye Capital’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Walleye Capital’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-86,641	Closed	-$186K	–	5761
2024 Q3	$186K	Sell	86,641 -199,162	-70%	-$715K	﹤0.01%	4051
2024 Q2	$1.47M	Buy	285,803 +867	+0.3%	+$4.56K	﹤0.01%	2417
2024 Q1	$1.52M	Buy	+284,936	New	+$1.97M	﹤0.01%	2196
2022 Q4	–	Sell	-12,800	Closed	-$82K	–	3721
2022 Q3	$82K	Buy	+12,800	New	+$104K	﹤0.01%	2488
2022 Q2	–	Sell	-5,609	Closed	-$67K	–	2773
2022 Q1	$67K	Buy	5,609 +4,509	+410%	+$80.6K	﹤0.01%	1810
2021 Q4	$36K	Sell	1,100 -2,223	-67%	-$90K	﹤0.01%	1821
2021 Q3	$149	Buy	+3,323	New	+$162K	﹤0.01%	1247

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Walleye Capital's SYRS Position: Q4 2024 in Review

Walleye Capital sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2024, closing a stake of 86,641 shares — an estimated $186K sold.

Walleye Capital first reported a position in SYRS in Q3 2021 and held it in 7 quarters. The position peaked at $1.52M in Q1 2024. 44 funds tracked by Wall St. Rank hold SYRS as of Q4 2024.

Walleye Capital reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Walleye Capital sold 86,641 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $186K.
Walleye Capital first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
Walleye Capital's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1.52M in Q1 2024.
44 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Walleye Capital's 13F filing for Q4 2024, filed 13 Feb 2025.